Intervention not reported
Cessation: Bupropion vs. placebo · Smokers who cannot or do not want to quit smoking
The intervention showed no clear difference in cessation: Bupropion vs. placebo (low certainty).
1 finding from 1 review
Smoking abstinence at longest · people who smoke
Varenicline leads to higher smoking abstinence at longest compared with bupropion (high certainty).
1 finding from 1 review
SAEs · people who smoke
Varenicline showed no clear difference in SAEs compared with bupropion (low certainty).
1 finding from 1 review
Neuropsychiatric SAEs · people who smoke
Varenicline showed no clear difference in neuropsychiatric SAEs compared with bupropion (low certainty).
1 finding from 1 review
Cardiac SAEs · people who smoke
Varenicline showed no clear difference in cardiac SAEs compared with bupropion (low certainty).
1 finding from 1 review
Failure to respond at endpoint (6‐12 weeks) · patients with depression
Paroxetine showed no clear difference in failure to respond at endpoint (6‐12 weeks) compared with bupropion (moderate certainty).
1 finding from 1 review
Failure to respond at 1‐4 weeks · patients with depression
1 finding from 1 review
Failure to respond at 16‐24 weeks · patients with depression
1 finding from 1 review
Failure to remit at endpoint · patients with depression
1 finding from 1 review
SMD at endpoint · patients with depression
1 finding from 1 review
Failure to complete ‐ any cause ‐ · patients with depression
Paroxetine showed no clear difference in failure to complete ‐ any cause ‐ compared with bupropion (moderate certainty).
1 finding from 1 review
Participants with at least some Side Effects · patients with depression
Paroxetine showed no clear difference in participants with at least some Side Effects compared with bupropion (moderate certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with bupropion (moderate certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ total ‐ compared with bupropion (moderate certainty).
1 finding from 1 review
Failure to complete ‐ inefficacy ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with bupropion (moderate certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with bupropion (moderate certainty).
1 finding from 1 review
Intervention not reported
Severity of ADHD (at study completion) WRAADDS scale (0 to 28), ADHD‐RS scale (0 to 54) or CAARS scale (0 to 48). On all scales, a higher score equates to more symptoms (at 6 weeks) · Adults with ADHD
1 finding from 1 review
Intervention not reported
Achievement of significant clinical improvement (% participants) (at 6 to 10 weeks) · Adults with ADHD
The intervention may leads to higher achievement of significant clinical improvement (% participants) (at… (low certainty).
1 finding from 1 review
Intervention not reported
CGI ‐ Improvement scale (% participants achieving at least 1 or 2 on CGI) (at 6 to 10 weeks) · Adults with ADHD
The intervention may leads to higher CGI ‐ Improvement scale (% participants achieving at least 1 or 2 on… (low certainty).
1 finding from 1 review